TNFAIP3 and diffuse large B-cell lymphoma: Tumor extracellular vesicles carrying miR‐125b‐5p enter diffuse large B‐cell lymphoma (DLBCL) cells and target TNFAIP3, thereby reducing the sensitivity of DLBCL to rituximab [46], and overexpression of TNFAIP3 is associated with a lower survival rate in breast cancer patients [47]; a study about ferroptosis after cerebral hemorrhage also find TNFAIP3 upregulation [48].